ReviewThe Journal of infectious diseases2008
The research agenda of the National Institute of Allergy and Infectious Diseases for antimicrobial resistance.
Review in The Journal of infectious diseases, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Genomics and pathotypes of the many faces of Escherichia coli.FEMS microbiology reviews · 2022Article
- Article
- Surveillance of Antibiotic-Resistant Bacteria in King Khalid Hospital, Hafr Al-Batin, Saudi Arabia, During 2013.Jundishapur journal of microbiology · 2016Article
- High-throughput screening of a diversity collection using biodefense category A and B priority pathogens.Journal of biomolecular screening · 2012Article
- Synthesis of lipoteichoic acids in Bacillus anthracis.Journal of bacteriology · 2012Article
- Influence of antibiotic susceptibility patterns on empiric antibiotic prescribing for children hospitalized with community-acquired pneumonia.The Pediatric infectious disease journal · 2012Article
- National Institute of Allergy and Infectious Disease (NIAID) Funding for Studies of Hospital-Associated Bacterial Pathogens: Are Funds Proportionate to Burden of Disease?Antimicrobial resistance and infection control · 2012Article
- Synergistic interactions of methanolic extract of Acacia mearnsii De Wild. with antibiotics against bacteria of clinical relevance.International journal of molecular sciences · 2012Article
- Combating antimicrobial resistance: policy recommendations to save lives.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2011Article
- Single nucleotide polymorphism analysis of the major tripartite multidrug efflux pump of Escherichia coli: functional conservation in disparate animal reservoirs despite exposure to antimicrobial chemotherapy.Antimicrobial agents and chemotherapy · 2010Article
- Dual-function antibodies to Yersinia pestis LcrV required for pulmonary clearance of plague.Clinical and vaccine immunology : CVI · 2009Article
- Discovery of a small molecule that blocks wall teichoic acid biosynthesis in Staphylococcus aureus.ACS chemical biology · 2009Article
- Antibiotic resistance: who will pay the bills?Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2009Article
- Public funding of clinical-stage antibiotic development in the United States and European Union.Health securityArticle
- A review of antibiotic use in food animals: perspective, policy, and potential.Public health reports (Washington, D.C. : 1974)Review
Corrections and comments
- Commented on by
- Commented on by
- Comment on
Authors and funding
4 authors.
Funding
Abstract
Antimicrobial resistance is an intrinsic and inevitable aspect of microbial survival that continually challenges human health. Research on antimicrobial resistance is central to the mission of the National Institute of Allergy and Infectious Diseases (NIAID). In fiscal year 2007, NIAID invested more than USD800 million to support basic and translational research on antimicrobials, more than USD200 million of which is devoted to understanding the causes, consequences, and treatments of antimicrobial drug resistance. The complex process that facilitates the transformation of ideas into therapies requires a pipeline that runs from bench to bedside, and NIAID has leveraged the entire spectrum of conventional and biodefense resources. NIAID works in partnership with other federal agencies, industry, foundation partners, and foreign governments. The basic and clinical research supported by NIAID will, ideally, continue to yield profound rewards in terms of the understanding, diagnosis, and treatment of infectious diseases.
Indexed as
Identifiers
18419527What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.